Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: A Swedish multicentre randomized trial

British Journal of Haematology

Volumn 124, Issue 4, 2004, Pages 474-480

  Lofgren C ^a   Paul, C ^a   Astrom M ^b   Hast, R ^a   Hedenius, M ^c   Lerner, R ^a,d   Liliemark, J ^a   Nilsson, I ^e   Rodjer S ^f   Simonsson, B ^g   Stockelberg, D ^f   Tidefelt, U ^b   Bjorkholm M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c SUNDSVALL HOSPITAL   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

^e Karlstad Hospital   (Sweden)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukaemia; Elderly; Granulocyte macrophage colony stimulating factor; Maintenance; Thioguanine

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMSACRINE; ANTIBIOTIC AGENT; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; EYE DROPS; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BLOOD CULTURE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONVALESCENCE; DRUG EFFECT; FEMALE; HUMAN; INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; SEPTICEMIA;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 10744223866     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.04805.x     Document Type: Article

References (27)

1. Andersson, J.E., Kopecky, K.J., Willman, C.L., Head, D., O'Donell, M.R., Luthardt, F.W., Norwood, T.H., Chen, I.M., Balcerzak, S.P., Johnson, S.P. & Appelbaum, F.R. (2002) Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicine: a Southwest Oncology Group Study. Blood, 100, 3869-3876.
2. Antman, K., Griffin, J., Elias, A., Socinski, M., Ryan, L., Cannistra, S., Oette, D., Whitley, M., Frei, E.R. & Schnipper, L. (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. New England Journal of Medicine, 319, 593-598.
3. Asano, S., Shibuya, T., Okamura, S., Yamaga, S., Otsuka, T. & Niho, Y. (1987) Effect of human recombinant granulocyte/macrophage colony-stimulating factor and native granulocyte colony-stimulating factor on clonogenic leukemic blast cells. Cancer Research, 47, 5647-5648.
4. Bennet, C.L., Hynes, D., Godwin, J., Stinson, T.J., Golub, R.M. & Appelbaum, F.R. (2001) Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group trial. Cancer Investigation, 19, 603-610.
5. Bennett, J., Catovsky, D., Daniel, M.-T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan C. (1976) Proposals for the classification of acute leukemias. British Journal of Haematology, 33, 451-458.
6. Bernstein, S., Brunetto, V., Davey, F., Wurster-Hill, D., Mayer, R., Stone, R., Schiffer, C. & Bloomfield, C. (1996) Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria; a Cancer and Leukemia Group B Study. Journal of Clinical Oncology, 14, 2486-2494.
7. Bettelheim, P., Valent, P., Andreff, M., Tafuri, A., Haimi, J., Gorischek, C., Muhm, M., Sillaber, C., Haas, O., Vieder, L., Maurer, D., Schultz, G., Spieser, W., Giessler, K., Kier, P., Hinterberger, W. & Lechner, K. (1991) Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood, 77, 700-711.
8. Björkholm, M., Bjornsdottir, J., Stenke, L. & Grimfors, G. (1990) Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia. Oncology, 47, 112-114.
9. Bjorkholm, M., Liliemark, J., Gahrton, G., Grimfors, G., Gruber, A., Hast, R., Juliusson, G., Jarnmark, M., Killander, A., Kimby, E., Lerner, R., Ljungman, P., Lonnquist, B., Palmblad, J., Paul, C., Petterson, C., Simonsson, B., Stalfelt, A.-M., Stenke, L., Sundstrom, C., Tidefelt, U., Uden, A.-M., Oberg, G., Ost, A. (1995) Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison. European Journal of Haematology, 55, 19-23.
10. Estey, E., Thall, P., Beran, M., Kantarjian, H., Pierce, S. & Keating, M. (1997) Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia (AML) on outcome of AML-type chemotherapy. Blood, 90, 2969-2977.
11. Estrov, Z., Estey, E., Andreeff, M., Talpaz, M., Kurzrock, R., Reading, C., Deisseroth, A. & Gutterman, J. (1992) Comparison of in vivo and in vitro effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with acute myeloid leukemia. Experimental Hematology, 20, 558-564.
12. Godwin, J.E., Kopecky, K., Head, D., Willman, C., Leith, C., Hynes, H., Balcerak, S. & Appelbaum, F. (1998) A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated myeloid leukemia: a Southwest Oncology Group study (9030). Blood, 91, 3607-3615.
13. Griffin, J., Young, D., Herrmann, F., Wiper, D., Wagner, K. & Sabbath, K. (1986) Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood, 67, 1448-1453.
14. Hast, R., Hellström-Lindberg, E., Ohm, L., Björkholm, M., Celsing, F., Dahl, I., Dybedal, I., Gahrton, G., Lindberg, G., Lerner, R., Linder, O., Löfvenberg, E., Nihlsson-Ehle, H., Paul, C., Samuelsson, J., Tangen, J., Tidefelt, U., Turesson, I., Wahlin, A., Wallvik, J., Winquist, I., Öberg, G. & Bernell, P. (2003) No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia, 9, 1827-1833.
15. Heil, G., Hoelzer, D., Sanz, M.A., Lechner, K., Yin, J.L., Papa, G., Noens, L., Szer, J., Ganser, A., O'Brien, C., Matcham, J. & Barge, A. (1997) A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood, 90, 4710-4718.
16. Kalaycio, M., Pohlman, B., Lichtin, A., Hussein, M., Tripp, B. & Andresen, S. (2001) Chemotherapy for AML in elderly with cytarabine, mitoxantrone and granulocyte-macrophage colony-stimulating factor. American Journal of Clinical Oncology, 24, 58-63.
17. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
18. Leith, C., Kopecky, K. & Goodwin, J. (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood, 89, 3323-3329.
19. Rees, J., Gray, R., Swirsky, D. & Hayhoe, F. (1986) Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet, 2, 1236-1241.
20. Rowe, J. (1998) Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clinical Infectious Diseases, 26, 1290-1294.
21. Rowe, J., Andersen, J. & Mazza, J. (1995) Randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia: a study of Eastern Cooperative Oncology Group (E1490). Blood, 332, 1671-1677.
22. Shepherd, J.D., Reece, D.E. & Barnett, M.J. (1993) Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide. Leukemia Lymphoma, 9, 211-215.
23. Slovak, M., Kopecky, K. & Cassileth, P. (1998) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood, 96, 4075-4083.
24. Stone, R.M., Berg, D.T., George, S.L., Dodge, R.K., Paciucci, P.A., Schulman, P., Lee, E.J., Moore, J.O., Powell, B.L. & Schiffer, C.A. (1995) Granulocyte-macrophage colony-stimulating factor alter initial chemotherapy for elderly patients with primary acute myelogenous leukemia cancer and leukemia group B. New England Journal of Medicine, 332, 1671-1677.
25. Stone, R., Berg, D., George, S., Dodge, R., Paciucci, P., Schulman, P., Lee, E., Moore, J., Powell, B., Baer, M., Bloomfield, C. & Schiffer, C. (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood, 98, 548-553.
26. Sundman-Engberg, B., Tidefelt, U. & Paul, C. (1996) Effect of cytokines on the toxicity of cytostatic drugs on leukemic cells in vitro and in vivo. European Journal of Haematology, 56, 1-6.
27. Tucker, J., Thomas, S., Gregpry, W., Ganesan, T., Malik, S., Lim, J.A., Willis, L., Rohatiner, A. & Lister, T. (1990) Acute myeloid leukemia in elderly adults. Hematology Oncology, 8, 13-21.